Last reviewed · How we verify
Cortisone Injectable
At a glance
| Generic name | Cortisone Injectable |
|---|---|
| Also known as | steroid |
| Sponsor | InGeneron, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Conservative Treatment of Trigger Finger (NA)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Hoffa's Fat Pad Impingement (HFPI) (PHASE4)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (PHASE3)
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
- Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cortisone Injectable CI brief — competitive landscape report
- Cortisone Injectable updates RSS · CI watch RSS
- InGeneron, Inc. portfolio CI